Evidence map›Paper›PMID 35874074›Full record

ArticleHeliyon2022

Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.

Joanna Kapeleris, Juliana Müller Bark, Shanon Ranjit, Darryl Irwin, Gunter Hartel, Majid Ebrahimi Warkiani, Paul Leo, Connor O'Leary, Rahul Ladwa, Kenneth O'Byrne and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Joanna KapelerisQueensland University of Technology, Faculty of Health, School of Biomedical Sciences, Centre for Biomedical Technologies, Saliva and Liquid Biopsy Translational Laboratory Kelvin Grove, QLD, Australia.
Juliana Müller BarkQueensland University of Technology, Faculty of Health, School of Biomedical Sciences, Centre for Biomedical Technologies, Saliva and Liquid Biopsy Translational Laboratory Kelvin Grove, QLD, Australia.
Shanon RanjitQueensland University of Technology, Faculty of Health, School of Biomedical Sciences, Centre for Biomedical Technologies, Saliva and Liquid Biopsy Translational Laboratory Kelvin Grove, QLD, Australia.
Darryl IrwinAgena Biosciences, Bowen Hills, Brisbane, QLD, Australia.
Gunter HartelQIMR Berghofer Medical Research Institute, Herston Road, Herston, QLD, Australia.
Majid Ebrahimi WarkianiSchool of Biomedical Engineering, University of Technology Sydney, Sydney, Ultimo NSW, Australia.
Paul LeoTranslational Research Institute, Woolloongabba, Brisbane, Australia.
Connor O'LearyTranslational Research Institute, Woolloongabba, Brisbane, Australia.
Rahul LadwaDepartment of Medical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Kenneth O'ByrneTranslational Research Institute, Woolloongabba, Brisbane, Australia.
Brett G M HughesSchool of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia.
Chamindie PunyadeeraTranslational Research Institute, Woolloongabba, Brisbane, Australia.
Translational Research Institute · AUGriffith University · AUThe University of Queensland · AUQIMR Berghofer Medical Research Institute · AUQueensland University of Technology · AUUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Non-small cell lung cancer (NSCLC) often presents at an incurable stage, and majority of patients will be considered for palliative treatment at some point in their disease. Despite recent advances, the prognosis remains poor, with a median overall survival of 12-18 months. Liquid biopsy-based biomarkers have emerged as potential candidates for predicting prognosis and response to therapy in NSCLC patients. This pilot study evaluated whether combining circulating tumour cells and clusters (CTCs) and cell-free DNA (cfDNA) can predict progression-free survival (PFS) in NSCLC patients. Methods: CTC and cfDNA/ctDNA from advanced stage NSCLC patients were measured at study entry (T Results: Single CTCs were found in 14 out of 25 patients, while CTC clusters were found in 8 out of the 25 patients at T Conclusions: Combining CTC cluster counts and cfDNA levels could improve PFS assessment in NSCLC patients. Our results encourage further investigation on the combined effect of CTC/cfDNA as a prognostic biomarker in a large cohort of advanced stage NSCLC patients.

Indexed as

Cell-free DNACirculating tumour cells and clustersCirculating tumour DNALiquid biopsyNon-small cell lung cancerProgression-free-survival

Identifiers

PMID35874074
PMCPMC9305346
OpenAlexW4285806335

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.